{
    "nct_id": "NCT06224192",
    "official_title": "A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost)",
    "inclusion_criteria": "* Age ≥ 12 at Day 1.\n* Diagnosis of AD according to American Academy of Dermatology (AAD) Consensus Criteria (2014) that has been present for at least 12 months.\n* History of inadequate response to Topical Corticosteroids (TCS) of medium to higher potency (with or without topical calcineurin inhibitors [TCI]).\n* Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ≥ 3 at screening and pre-randomization.\n* Eczema Area and Severity Index (EASI) score ≥ 16 at initial at screening and pre-randomization.\n* ≥ 10% body surface area (BSA) of AD involvement at screening and pre-randomization.\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization.\n* Treatment with any of the following medications or therapies within 5 half-lives prior to day 1 pre-randomization:\n\n  1. Systemic corticosteroids\n  2. Non-biologic, non-targeted systemic immunosuppressants\n  3. Oral or Topical Janus kinase inhibitors\n* Treatment with any of the following medications or therapies within 1 week before day 1 pre-randomization:\n\n  1. Topical phosphodiesterase 4 (PDE4) inhibitors\n  2. Other topical immunosuppressive agents (not including TCS/TCI)\n  3. Combination topical agents containing any of the above components",
    "miscellaneous_criteria": ""
}